Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk
- PMID: 19820206
- PMCID: PMC2773186
- DOI: 10.1093/jnci/djp331
Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk
Abstract
Background: Müllerian inhibiting substance (MIS) is a member of the transforming growth factor beta family of growth and differentiation factors that inhibits elongation and branching of mammary ducts and has been shown to inhibit mammary tumor growth in vitro and in animal models. The objective of this study was to determine whether serum MIS levels are associated with breast cancer risk.
Methods: We conducted a prospective case-control study of 309 participants who were registered in the Columbia, Missouri Serum Bank. Each of 105 in situ or invasive breast cancer case patients with prediagnostic serum collected before menopause was matched to two control subjects by age, date, menstrual cycle day, and time of day of blood collection. MIS was measured in serum by using an enzyme-linked immunosorbent assay, and estradiol and testosterone concentrations were quantified by using specific radioimmunoassays. Data were analyzed using conditional logistic regression. All tests of statistical significance were two-sided.
Results: The relative odds ratio of breast cancer for women in increasing MIS quartiles were 1, 2.8 (95% confidence interval [CI] = 1.0 to 7.4), 5.9 (95% CI = 2.4 to 14.6), and 9.8 (95% CI = 3.3 to 28.9, P(trend) < .001). The association of MIS with breast cancer was weaker in women who were not taking oral contraceptives at the time of blood collection, but adjustment for estradiol and testosterone levels did not materially alter results for these women. The association of MIS with breast cancer did not vary by age at blood collection but was stronger among women who were diagnosed with breast cancer at an older age than among those who were diagnosed at a younger age.
Conclusion: MIS may be a novel biomarker of increased breast cancer risk. Additional research including confirmatory epidemiological studies and mechanistic studies is needed.
Figures

Similar articles
-
Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk.Breast Cancer Res. 2010;12(6):R98. doi: 10.1186/bcr2779. Epub 2010 Nov 18. Breast Cancer Res. 2010. PMID: 21087481 Free PMC article.
-
Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).J Natl Cancer Inst. 2005 May 18;97(10):755-65. doi: 10.1093/jnci/dji132. J Natl Cancer Inst. 2005. PMID: 15900045
-
Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):854-60. doi: 10.1158/1055-9965.EPI-15-1240. Epub 2016 Mar 9. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26961996 Free PMC article.
-
Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk.Cancer Prev Res (Phila). 2015 Jun;8(6):528-34. doi: 10.1158/1940-6207.CAPR-14-0377. Epub 2015 Apr 14. Cancer Prev Res (Phila). 2015. PMID: 25873369 Free PMC article.
-
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15. doi: 10.1093/jnci/djj376. J Natl Cancer Inst. 2006. PMID: 17018787
Cited by
-
Circulating Hormones and Mammographic Density in Premenopausal Women.Horm Cancer. 2018 Apr;9(2):117-127. doi: 10.1007/s12672-017-0321-6. Epub 2018 Jan 12. Horm Cancer. 2018. PMID: 29330698 Free PMC article.
-
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.Future Oncol. 2010 Mar;6(3):391-405. doi: 10.2217/fon.09.172. Future Oncol. 2010. PMID: 20222796 Free PMC article. Review.
-
Serum antimüllerian hormone in healthy premenopausal women.Fertil Steril. 2011 Jun 30;95(8):2718-21. doi: 10.1016/j.fertnstert.2011.05.051. Fertil Steril. 2011. PMID: 21704216 Free PMC article.
-
Genetic variants in anti-Müllerian hormone-related genes and breast cancer risk: results from the AMBER consortium.Breast Cancer Res Treat. 2021 Jan;185(2):469-478. doi: 10.1007/s10549-020-05944-4. Epub 2020 Sep 22. Breast Cancer Res Treat. 2021. PMID: 32960377 Free PMC article.
-
Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.Br J Cancer. 2017 Oct 24;117(9):1412-1418. doi: 10.1038/bjc.2017.299. Epub 2017 Sep 5. Br J Cancer. 2017. PMID: 28873086 Free PMC article.
References
-
- Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev. 2001;22(5):657–674. - PubMed
-
- Lee MM, Donahoe PK, Hasegawa T, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996;81(2):571–576. - PubMed
-
- de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357–362. - PubMed
-
- van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83(4):979–987. - PubMed
-
- Segev DL, Hoshiya Y, Stephen AE, et al. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo. J Biol Chem. 2001;276(29):26799–26806. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical